Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Julie Lecuelle, Caroline Truntzer, Debora Basile, Luigi Laghi, Luana Greco, et al.. Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts. EBioMedicine, 2024, 105, pp.105207. ⟨10.1016/j.ebiom.2024.105207⟩. ⟨hal-04626841⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
Johanne Seguin, Mostafa El Hajjam, Josette Legagneux, Sarah Diakhaby, Nathalie Mignet, et al.. Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma. Pharmaceutics, 2024, 16 (3), pp.315. ⟨10.3390/pharmaceutics16030315⟩. ⟨hal-04626840⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
Mots clés
Staging
Circulating cell-free DNA
Colorectal cancer
Prevention
TNM classification
Melanoma
Metastatic
Polyomavirus
Lung adenocarcinoma
Anti-PD-1
Resistance
Adjuvant therapy
Anti-PD1 blockade
Trametinib
AZD9291
ACTH
Immunomodulation
Antibody-drug conjugate
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
BRAFV600-mutant melanoma
Non-small cell lung cancer
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Plasma
Beta-catenin
Advanced
Targeted therapy
Merkel cell carcinoma
Cemiplimab
Systemic therapy
EGFR
Crizotinib
Langerhans cell histiocytosis
Bisphosphonates
Biomarker
Circulating tumor DNA
Cutaneous squamous cell carcinoma
Osimertinib
Acute generalized exanthematous pustulosis
Surgical excision
ALK rearrangement
AML
Immunohistochemistry
Wnt
Treatment
2-chlorodeoxyadenosine
Safety
Biliopancreatic diversion
Nivolumab
Mesenchymal stromal cells
Anti-PD1
Invasive cutaneous squamous cell carcinoma
Cancer bronchique non à petites cellules
Anti-PD-1 antibody
Radiotherapy
Diagnosis
ADN tumoral circulant
Colorectal carcinoma
Prognostic
Immune checkpoint inhibitor
Allelic imbalance
Antineoplastic agents
Adjuvant
Immunotherapy
Assisted reproductive techniques
Prognosis
Biomarkers
Metastatic cSCC
Sonic Hedgehog
Histiocytosis
BRAFV600E
Adjuvant FOLFOX
BRAF V600E
Cancer
Bariatric surgery
Molecular targeted therapies
Chemotherapy
ALK
BRAFV600E mutation
Anti-CTLA-4
BRAF
Survival
Follow-up
Locally advanced
Chemoresistance
Abscopal effect
BRAF V600-mutation
Oncology
Androgen insensitivity
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Liver metastases
Gastric bypass
Colon cancer
Anti-Tumor pharmacology
Children
Radiofrequency ablation
Abdominal pain
Dabrafenib
Adverse events
Advanced melanoma
Body mass index